Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium.

Tzanakis, Ioannis; Pras, A.; Kounali, Daphne‐Zacharenia; Mamali, V.; Kartsonakis, V.; Mayopoulou-Symvoulidou, D.; Kallivretakis, N.

doi:10.1093/ndt/12.9.2036

Cited by 59 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum Mg was previously reported to be significantly lower in peritoneal dialysis (PD) and HD patients with vascular calcification than in patients without calcification [13,15,16]. Low serum Mg was also reported to be related to a higher prevalence of mitral valve calcification among HD patients [14]. These observations raise the possibility that magnesium supplements may have a role in the prevention of vascluar calcification.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Peripheral Vascular Calcification and Serum Magnesium Level in a Group of Egyptian Hemodialysis Patients

Okasha¹,

Bendary²,

Mourad³

2010

Arab J. Nephr. Trans

View full text Add to dashboard Cite

Introduction: Vascular calcification is a risk factor for cardiovascular mortality in the general population. It is highly prevalent in end stage renal disease (ESRD) patients. Low magnesium (Mg) levels have been reported to have a strong association with vascular calcification in hemodialysis (HD) patients. The aims of this study were to evaluate the prevalence of vascular calcification and its relation to serum Mg concentration in a group of Egyptian HD patients. Methods:We studied 65 stable patients undergoing maintenance HD for more than 6 months. Vascular calcification was evaluated using hand roentgenography. Serum Mg, phosphorus, corrected calcium and intact parathyroid hormone (iPTH) levels were compared between patients with and without vascular calcification. Results:The study included 41 male and 24 female patients, aged 43-70 years. Vascular calcification was present in 38.5% of the patients. Mean serum Mg level was 2.88 ± 0.51 mg/dl. Male gender was more common in patients with vascular calcification, and they had significantly longer HD duration and significantly higher serum phosphorus and iPTH levels. Serum Mg level was significantly lower in patients with vascular calcification (2.36 ± 0.26 mg/dl vs.3.21 ± 0.32 mg/dl, p = 0.001). Serum Mg concentration remained as independent negative predictor of hand-artery vascular calcification after adjustment for age, gender, duration of HD, serum phosphorus and iPTH levels. Conclusion:Vascular calcification is common in the study population and is associated with a lower serum Mg level. High or sustained-normal Mg levels may have a protective role against the development of vascular calcification in HD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several studies found a significant inverse relationship between serum Mg and vascular calcification in HD patients [12,14,15]. In this study, we examined serum Mg levels and peripheral arterial calcification of the hand among a group of Egyptian non-diabetic patients undergoing maintenance HD.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Peripheral Vascular Calcification and Serum Magnesium Level in a Group of Egyptian Hemodialysis Patients

Okasha¹,

Bendary²,

Mourad³

2010

Arab J. Nephr. Trans

View full text Add to dashboard Cite

show abstract

“…Limited information is currently available on the effects of Mg on arrhythmia, but Alabd et al reported that the post-dialysis QTc interval duration inversely correlated with a decrease in serum Mg levels during the HD session [61]. Table 1 shows observational studies that examined the relationship between serum Mg levels and cardiovascular calcification/atherosclerosis in CKD/ESRD patients [32,[62][63][64][65][66][67][68]. Most of these studies indicated an association between hypomagnesemia and cardiovascular lesions.…”

Section: Mg and Dialysis Therapymentioning

confidence: 99%

Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions

Ikee¹

2018

Ren Replace Ther

View full text Add to dashboard Cite

Magnesium (Mg) is an essential element that plays pivotal roles in a number of biological processes in the human body. Hypomagnesemia is involved in the pathophysiology of hypertension, vascular calcification, and metabolic derangements including diabetes mellitus and dyslipidemia, which are all risk factors for cardiovascular disease, the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD). Hypomagnesemia is also associated with the development and progression of CKD. As CKD advances, renal Mg excretion decreases and hypermagnesemia emerges in end-stage renal disease (ESRD). In addition, dialysates with high Mg concentrations, which were used in the early era of dialysis therapy, increased the risk of hypermagnesemia, and thus, the dialysate Mg composition has since been reduced. Accordingly, dialysis patients in the modern era commonly have normomagnesemia or even hypomagnesemia. The relationships between hypomagnesemia and cardiovascular disease and mortality have been increasingly reported in observational studies in CKD/ESRD. However, these relationships may be attenuated by a patient's race or region. Although dialysates with higher Mg concentrations or Mg-containing phosphate binders appear to be promising in this setting, only a few interventional studies have examined the effects of Mg supplementation on cardiovascular lesions. Furthermore, the effects of Mg supplementation on mortality have not yet been investigated as a primary end-point in randomized controlled trials. Further studies are required in order to establish the efficacy and safety of Mg in CKD patients.

show abstract

“…Few clinical studies have demonstrated that lower serum magnesium levels are associated with vascular calcification and mortality in CKD stage 5D patients [14][15][16][17] . Moreover, hypermagnesaemia inhibits parathyroid hormone (PTH) secretion [18,19] , which is considered an independent risk factor for vascular calcification [20] , left ventricular hypertrophy [21] and mortality [22,23] in CKD patients.…”

Section: Introductionmentioning

confidence: 99%

Lower Serum Magnesium Is Associated with Cardiovascular Risk Factors and Mortality in Haemodialysis Patients

et al. 2014

View full text Add to dashboard Cite

Background: Hypomagnesaemia is a cardiovascular (CV) risk factor in the general population. The aim of this study was to evaluate the relationship between pre-dialysis magnesium (Mg) and CV risk markers, [including pulse pressure (PP), left ventricular mass index (LVMI) and vascular calcifications (VC)], and mortality in haemodialysis (HD) patients. Methods: We performed a 48-month prospective study in 206 patients under pre-dilution haemodiafiltration with a dialysate Mg concentration of 1 mmol/l. Results: Lower Mg concentrations were predictors of an increased PP (≥65 mm Hg) (p = 0.002) and LVMI (≥140 g/m2) (p = 0.03) and of a higher VC score (≥3) (p = 0.01). Patients with Mg <1.15 mmol/l had a lower survival at the end of the study (p = 0.01). Serum Mg <1.15 mmol/l was an independent predictor of all-cause (p = 0.01) and CV mortality (p = 0.02) when adjusted for multiple CV risk factors. Conclusions: Lower Mg levels seem to be associated with increased CV risk markers, like PP, LVMI and VC, and with higher mortality in HD patients.

show abstract

Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium.

Cited by 59 publications

References 0 publications

Evaluation of Peripheral Vascular Calcification and Serum Magnesium Level in a Group of Egyptian Hemodialysis Patients

Evaluation of Peripheral Vascular Calcification and Serum Magnesium Level in a Group of Egyptian Hemodialysis Patients

Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions

Lower Serum Magnesium Is Associated with Cardiovascular Risk Factors and Mortality in Haemodialysis Patients

Contact Info

Product

Resources

About